Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy

Sponsor
Swiss Cancer Institute
Study ID
NCT00003757
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy consisting of rituximab in treating patients with refractory or recurrent hairy cell leukemia following cladribine therapy.

Key Dates

Start date
Feb 28, 1998
Status verified
May 2012
Primary completion
Jul 31, 2002
Completion
Jul 31, 2007

Study Design

Enrollment
25 participants (estimated)
Primary purpose
TREATMENT

Related Studies